NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india)
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

Acceleron Pharma Inc (F: 0A3)

 
0A3 Technical Analysis
5
As on 22nd Nov 2021 0A3 STOCK Price closed @ 159.00 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 102.69 & Strong Buy for SHORT-TERM with Stoploss of 95.95 we also expect STOCK to react on Following IMPORTANT LEVELS.
 
 

0A3STOCK Price

Open 159.00 Change Price %
High 159.00 1 Day 0.00 0.00
Low 159.00 1 Week 8.00 5.30
Close 159.00 1 Month 9.00 6.00
Volume N/A 1 Year 63.50 66.49
52 Week High 159.00 | 52 Week Low 87.50
 
F Germany Most Active Stocks
IMU 0.10 %
IMU 0.10 %
IMU 0.10 %
IMU 0.10 %
IMU 0.10 %
ENB 47.60 -0.92%
TEF 3.84 -0.52%
TEF 3.84 -0.52%
WHL 5150.00 -0.44%
WDI 0.05 -37.50%
 
F Germany Top Gainers Stocks
0AI 11.30 14025.00%
0AI 11.30 14025.00%
SUE1 12.60 12500.00%
WPIA 6.22 871.88%
WPIA 6.22 871.88%
WPIA 6.22 871.88%
8S3B 1.73 620.83%
8S3B 1.73 620.83%
SY7P 0.07 600.00%
P9F1 1.75 326.83%
 
F Germany Top Losers Stocks
TINC 0.01 -99.92%
TINC 0.01 -99.92%
TINC 0.01 -99.92%
LDB 1.71 -92.57%
LDB 1.71 -92.57%
LDB 1.71 -92.57%
LDB 1.71 -92.57%
LDB 1.71 -92.57%
AETG 0.25 -91.61%
AETG 0.25 -91.61%
 
 
0A3
Daily Charts
0A3
Intraday Charts
Whats New @
Bazaartrend
0A3
Free Analysis
 
0A3 Important Levels Intraday
RESISTANCE159.00
RESISTANCE159.00
RESISTANCE159.00
RESISTANCE159.00
RESISTANCE159.00
RESISTANCE159.00
RESISTANCE159.00
RESISTANCE159.00
 
0A3 Forecast June 2024
4th UP Forecast185.01
3rd UP Forecast176.67
2nd UP Forecast171.51
1st UP Forecast166.36
1st DOWN Forecast151.64
2nd DOWN Forecast146.49
3rd DOWN Forecast141.33
4th DOWN Forecast132.99
 
0A3 Weekly Forecast
4th UP Forecast180.20
3rd UP Forecast173.40
2nd UP Forecast169.20
1st UP Forecast165.00
1st DOWN Forecast153.01
2nd DOWN Forecast148.80
3rd DOWN Forecast144.60
4th DOWN Forecast137.80
 
0A3 Forecast2024
4th UP Forecast296.78
3rd UP Forecast252.59
2nd UP Forecast225.28
1st UP Forecast197.97
1st DOWN Forecast120.03
2nd DOWN Forecast92.72
3rd DOWN Forecast65.41
4th DOWN Forecast21.22
 
 
0A3 Other Details
Segment EQ
Market Capital 9222254592.00
Sector Healthcare
Industry Biotechnology
Offical website >
 
0A3 Address
0A3
 
0A3 Latest News
 
Your Comments and Response on Acceleron Pharma Inc
 
0A3 Business Profile
Acceleron Pharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. It offers REBLOZYL (luspatercept-aamt), a first-in-class erythroid maturation agent, for the treatment of anemia in adult patients with beta-thalassemia and transfusion-dependent anemia. The company is also developing Sotatercept, an activin receptor type IIA fusion protein, for the treatment of patients with pulmonary arterial hypertension; ACE-1334, a pulmonary therapeutic candidate that is in Phase I clinical trials; and luspatercept-aamt for non-transfusion-dependent beta-thalassemia patients and lower-risk myelodysplastic syndrome patients. It has a license agreements with the Salk Institute for Biological Studies for the cloning of type II activin receptors; and license agreement with Fulcrum Therapeutics, Inc. to identify small molecules designed to modulate specific pathways associated with a targeted indication within the pulmonary disease space. The company was formerly known as Phoenix Pharma, Inc. Acceleron Pharma Inc. was incorporated in 2003 and is headquartered in Cambridge, Massachusetts. Address: 128 Sidney Street, Cambridge, MA, United States, 02139
 
© 2005-2023 BazaarTrend.com All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service